[Chemo-endocrine therapy with high dose medroxyprogesterone acetate for recurrent or advanced breast cancer].
The endocrine therapy with high-dose medroxyprogesterone acetate (MPA) was applied for 19 patients with recurrent breast cancer and 3 with advanced breast cancer. According to the dominant lesion of the disease, the patients were divided into three groups; 13 with soft tissue lesion, 5 with visceral lesion, and 4 with osseous lesion. The serum MPA level was higher than 25 ng/ml in 14 cases out of 19 examined. The results of objective responses in second-line therapy with MPA were CR in two cases, and NC or PD in 20 cases. In 19 out of 22 patients with MPA therapy, the periods of survival were longer than the period of 50% survival of the patients without MPA therapy.
Maeda
T
T
First Dept. of Surgery, Asahikawa Medical College.
Kubo
Y
Y
Sasajima
T
T
Ikeda
K
K
Hirata
S
S
Yamazaki
K
K
Nakajima
S
S
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D015996:Survival Rate
D017258:Medroxyprogesterone Acetate